Kaya Holdings Past Earnings Performance

Past criteria checks 2/6

Kaya Holdings has been growing earnings at an average annual rate of 3.4%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been declining at an average rate of 18.8% per year.

Key information

3.4%

Earnings growth rate

1.6%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-18.8%
Return on equityn/a
Net Margin820.0%
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Kaya Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:KAYS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230210
30 Sep 230320
30 Jun 230-620
31 Mar 231-220
31 Dec 221-420
30 Sep 221-320
30 Jun 221820
31 Mar 2211420
31 Dec 2111020
30 Sep 2111120
30 Jun 211-620
31 Mar 211-1720
31 Dec 201-1220
30 Sep 201-1730
30 Jun 201-230
31 Mar 201330
31 Dec 191830
30 Sep 191220
30 Jun 191220
31 Mar 191-420
31 Dec 181540
30 Sep 181-640
30 Jun 181-730
31 Mar 181130
31 Dec 171-1530
30 Sep 171-1620
30 Jun 171-1720
31 Mar 171-2320
31 Dec 161-2020
30 Sep 161-120
30 Jun 161-120
31 Mar 161-210
31 Dec 150-320
30 Sep 150-410
30 Jun 150-410
31 Mar 150-320
31 Dec 140-210
30 Sep 140-110
30 Jun 140-110
31 Mar 140000
31 Dec 130000
30 Sep 130000

Quality Earnings: KAYS has a large one-off gain of $537.3K impacting its last 12 months of financial results to 31st December, 2023.

Growing Profit Margin: KAYS became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: KAYS has become profitable over the past 5 years, growing earnings by 3.4% per year.

Accelerating Growth: KAYS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: KAYS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).


Return on Equity

High ROE: KAYS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.